Novel vaccine development strategies for inducing mucosal immunity
- 9 January 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Vaccines
- Vol. 11 (3), 367-379
- https://doi.org/10.1586/erv.11.196
Abstract
To develop protective immune responses against mucosal pathogens, the delivery route and adjuvants for vaccination are important. The host, however, strives to maintain mucosal homeostasis by responding to mucosal antigens with tolerance, instead of immune activation. Thus, induction of mucosal immunity through vaccination is a rather difficult task, and potent mucosal adjuvants, vectors or other special delivery systems are often used, especially in the elderly. By taking advantage of the common mucosal immune system, the targeting of mucosal dendritic cells and microfold epithelial cells may facilitate the induction of effective mucosal immunity. Thus, novel routes of immunization and antigen delivery systems also show great potential for the development of effective and safe mucosal vaccines against various pathogens. The purpose of this review is to introduce several recent approaches to induce mucosal immunity to vaccines, with an emphasis on mucosal tissue targeting, new immunization routes and delivery systems. Defining the mechanisms of mucosal vaccines is as important as their efficacy and safety, and in this article, examples of recent approaches, which will likely accelerate progress in mucosal vaccine development, are discussed.Keywords
This publication has 140 references indexed in Scilit:
- Secretory IgA-mediated protection againstV. choleraeand heat-labile enterotoxin-producing enterotoxigenicEscherichia coliby rice-based vaccineProceedings of the National Academy of Sciences of the United States of America, 2010
- Id2-, RORγt-, and LTβR-independent initiation of lymphoid organogenesis in ocular immunityThe Journal of Experimental Medicine, 2009
- Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate SystemsJournal of Pharmaceutical Sciences, 2009
- Ovalbumin-Protein σ1 M-Cell Targeting Facilitates Oral Tolerance With Reduction of Antigen-Specific CD4+ T CellsGastroenterology, 2008
- A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunityVaccine, 2008
- Sublingual vaccination with influenza virus protects mice against lethal viral infectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Novel Nanomaterials for Clinical NeuroscienceJournal of Neuroimmune Pharmacology, 2008
- A novel M cell–specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responsesThe Journal of Experimental Medicine, 2007
- Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccinationProceedings of the National Academy of Sciences of the United States of America, 2007
- Flt3 Ligand–treated Neonatal Mice Have Increased Innate Immunity Against Intracellular Pathogens and Efficiently Control Virus InfectionsThe Journal of Experimental Medicine, 2003